Schizophrenia : News

Healthline's Premium Tools

Pill Finder
Search by color, shape and markings. click here
Drug Interaction Checker
Check any 2 drugs for interactions. click here
Drug Compare
Compare any two drugs side by side. click here
Healthline Part D Plan Selector Medicare Part D
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
The Committee for Medicinal Products for Human Use has recommended European approval of Olanzapine Long-acting Injection , known in Europe by the trade name Zypadhera , for maintenance treatment of adult ...
Source:Drugs.com
Date:September 30, 2008
The Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Zypadhera for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during ...
Source:Med Ad News
Date:September 26, 2008
In a recent Value in Health article, researchers from the University of Southern California School of Pharmacy have documented the sensitivity of head-to-head drug comparisons based on existing data to sample ...
Source:MediLexicon
Date:September 25, 2008
Although many people do not worry about developing the psychiatric disorder schizophrenia, as less than 1 percent of people feel the effects of the disease over their lifetime, some have to deal with the ...
Source:Millbrook Round Table
Date:September 25, 2008
Sep 23, 2008 - In a new paper published in the online open-access journal PLoS ONE, http://dx.plos.org/10.1371/journal.pone.0003150, David Pickar and colleagues of Gabriel Sciences report that 74.5% of 200 ...
Source:Drugs.com
Date:September 22, 2008
The second-generation antipsychotics risperidone and olanzapine are no more effective than the first-generation drug molindone in treating early-onset schizophrenia and schizoaffective disorder, according to a ...
Source:Rehab Management
Date:September 20, 2008
AUSTIN Texas has spent nearly $300 million since 2003 on expensive anti-psychotic medications for poor children drugs that cost more, have worse side effects in kids and are no more effective than older ...
Source:KAUZ
Date:September 19, 2008
THE newer drugs for treating schizophrenia have come under such a cloud in recent years that it's no surprise to learn of another setback: they work no better than an older, less expensive drug in children and ...
Source:Whittier Daily News
Date:September 18, 2008
Memory Pharmaceuticals Corp. today announced that it has amended its nicotinic alpha-7 receptor agonist agreement with Roche to expand the Phase 2 development program for R3487/MEM 3454 in cognitive impairment ...
Source:The South Mississippi Sun Herald
Date:September 17, 2008
Mylan Inc. received approval from the Food and Drug Administration to manufacture and market Risperidone tablets, used to treat schizophrenia and bipolar disorder.
Source:PittsburghLIVE.com
Date:September 16, 2008
Mylan Inc today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Risperidone Tablets ...
Source:Medical News
Date:September 16, 2008
Ingram Micro Inc. said Tuesday that it has cut its expected revenue for the third quarter to range from $8.3 billion to $8.6 billion.
Source:MarketWatch
Date:September 16, 2008
The two most frequently prescribed antipsychotic drugs for children and adolescents offer no additional benefit and are more likely to cause side effects than an older, less costly medication, according to a ...
Source:Medical News
Date:September 16, 2008
A comparison of medications for severe mental illness shows that an old drug works just as well as new ones for teenagers, plus it doesn't cause the weight gain that has worried patients, parents and doctors, ...
Source:The Modesto Bee
Date:September 16, 2008
When scientists learned that PCP can cause every single symptom of schizophrenia, they wondered if chemicals that have the opposite effect could fight mental disorders.
Source:Wired News
Date:September 16, 2008
Advertisement
Back to Top